Skip to content

Zymeworks ZYME Change in AR

Change in AR at other companies

Pfizer logo
PfizerPFE
$65.75M+141%
Amgen logo
AmgenAMGN
-$413M-132%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$1.49M-212%
Septerna, Inc. logo
Septerna, Inc.SEPN
$486K+515%
TG Therapeutics logo
TG TherapeuticsTGTX
$86.42M+41.8%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$65.32M+123%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's change in AR?
Zymeworks (ZYME) reported change in AR of $36K in Q1 2026.
How has Zymeworks's change in AR changed year-over-year?
Zymeworks's change in AR increased by 100.1% year-over-year, from -$31.22M to $36K.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.